Patents by Inventor Michael Stephen Pacey

Michael Stephen Pacey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7271158
    Abstract: The invention described herein relates to: the use of an effective inhibitor of a bacterial ?-amylase and/or ?-glucosidase in the manufacture of a composition for the treatment of acidosis; a method of treatment of rumen acidosis which comprises administration of an effective amount of an effective inhibitor of a bacterial ?-amylase and/or ?-glucosidase to a ruminant; a formulation suitable for the treatment of acidosis in an animal which comprises an effective inhibitor of a bacterial ?-amylase and/or ?-glucosidase in admixture with a suitable excipient, diluent or carrier selected with regard to the intended route of administration and standard pharmaceutical/veterinary/farming practice; screening methods useful in the identification of a suitable inhibitor of a bacterial ?-amylase and/or ?-glucosidase for the treatment of acidosis in a ruminant; a process for improving ruminant milk quality and/or quantity which comprises treatment of a ruminant with an effective amount of an inhibitor of bacterial ?-amyla
    Type: Grant
    Filed: February 6, 2004
    Date of Patent: September 18, 2007
    Assignee: Pfizer Inc.
    Inventors: Bernard Joseph Banks, Mark Andrew Haxell, Graham Lunn, Michael Stephen Pacey, Lee Richard Roberts
  • Patent number: 7022684
    Abstract: The invention described herein relates to: the use of an effective inhibitor of a bacterial ?-amylase and/or ?-glucosidase in the manufacture of a composition for the treatment of rumen acidosis; a method of treatment of rumen acidosis which comprises administration of an effective amount of an effective inhibitor of a bacterial ?-amylase and/or ?-glucosidase to a ruminant; a formulation suitable for the treatment of rumen acidosis in an animal which comprises an effective inhibitor of a bacterial ?-amylase and/or ?-glucosidase in admixture with a suitable excipient, diluent or carrier selected with regard to the intended route of administration and standard pharmaceutical/veterinary/farming practice; screening methods useful in the identification of a suitable inhibitor of a bacterial ?-amylase and/or ?-glucosidase for the treatment of acidosis in a ruminant; a process for improving ruminant milk quality and/or quantity which comprises treatment of a ruminant with an effective amount of an inhibitor of bacte
    Type: Grant
    Filed: January 29, 2002
    Date of Patent: April 4, 2006
    Assignee: Pfizer Inc.
    Inventors: Bernard Joseph Banks, Mark Andrew Haxell, Graham Lunn, Michael Stephen Pacey, Lee Richard Roberts
  • Publication number: 20040167082
    Abstract: The invention described herein relates to: the use of an effective inhibitor of a bacterial &agr;-amylase and/or &agr;-glucosidase in the manufacture of a composition for the treatment of acidosis; a method of treatment of rumen acidosis which comprises administration of an effective amount of an effective inhibitor of a bacterial &agr;-amylase and/or &agr;-glucosidase to a ruminant; a formulation suitable for the treatment of acidosis in an animal which comprises an effective inhibitor of a bacterial &agr;-amylase and/or &agr;-glucosidase in admixture with a suitable excipient, diluent or carrier selected with regard to the intended route of administration and standard pharmaceutical/veterinary/farming practice; screening methods useful in the identification of a suitable inhibitor of a bacterial &agr;-amylase and/or &agr;-glucosidase for the treatment of acidosis in a ruminant; a process for improving ruminant milk quality and/or quantity which comprises treatment of a ruminant with an effective amount of a
    Type: Application
    Filed: February 6, 2004
    Publication date: August 26, 2004
    Applicant: Pfizer Inc
    Inventors: Bernard Joseph Banks, Mark Andrew Haxell, Graham Lunn, Michael Stephen Pacey, Lee Richard Roberts
  • Patent number: 6610518
    Abstract: The following invention relates to a process for oxidizing alkyl groups attached directly or via a linker, to a sulfonamide moiety (II) by the use of cytochrome P450 enzymes, to give the corresponding alcohol or carboxylic acid (I). wherein R is an organic radical, X is a linker, Y is —C(CH3)2— or —CH(CH3)— and Z is —CH2OH or —COOH.
    Type: Grant
    Filed: May 29, 2001
    Date of Patent: August 26, 2003
    Assignees: Pfizer Inc., Pfizer Products Inc.
    Inventor: Michael Stephen Pacey
  • Publication number: 20030060424
    Abstract: The invention described herein relates to: the use of an effective inhibitor of a bacterial &agr;-amylase and/or &agr;-glucosidase in the manufacture of a composition for the treatment of acidosis; a method of treatment of rumen acidosis which comprises administration of an effective amount of an effective inhibitor of a bacterial &agr;-amylase and/or &agr;-glucosidase to a ruminant; a formulation suitable for the treatment of acidosis in an animal which comprises an effective inhibitor of a bacterial &agr;-amylase and/or &agr;-glucosidase in admixture with a suitable excipient, diluent or carrier selected with regard to the intended route of administration and standard pharmaceutical/veterinary/farming practice; screening methods useful in the identification of a suitable inhibitor of a bacterial &agr;-amylase and/or &agr;-glucosidase for the treatment of acidosis in a ruminant; a process for improving ruminant milk quality and/or quantity which comprises treatment of a ruminant with an effective amount of a
    Type: Application
    Filed: January 29, 2002
    Publication date: March 27, 2003
    Applicant: Pfizer Inc.
    Inventors: Bernard Joseph Banks, Mark Andrew Haxell, Graham Lunn, Michael Stephen Pacey, Lee Richard Roberts
  • Patent number: 6437151
    Abstract: Erythromycins, particularly ones with novel C-13 substituents R1 (e.g. C3-C6 cycloalkyl or cycloalkenyl groups) are prepared by fermenting suitable organisms in the presence of R1CO2H. A preferred organism is Saccharopolyspora erythraea preferably containing an integrated plasmid capable of directing synthesis of desired compounds.
    Type: Grant
    Filed: June 29, 2001
    Date of Patent: August 20, 2002
    Assignees: Biotica Technology Limited, Pfizer Inc.
    Inventors: Peter Francis Leadlay, James Staunton, Jesus Cortes, Michael Stephen Pacey
  • Patent number: 6387915
    Abstract: Isoxazole-sulfonamide endothelin antagonists of formula (I) below having good affinity for endothelin receptors and selectivity for ETA over ETB are described herein. Such compounds are useful in the treatment of conditions mediated by endothelin, in particular, conditions mediated by endothelin ETA.
    Type: Grant
    Filed: May 30, 2001
    Date of Patent: May 14, 2002
    Assignee: Pfizer Inc.
    Inventors: Bernard Joseph Banks, Nathan Anthony Logan Chubb, James John Eshelby, Michael Stephen Pacey, Darren John Schulz
  • Publication number: 20020019408
    Abstract: Isoxazole-sulfonamide endothelin antagonists of formula (I) below having good affinity for endothelin receptors and selectivity for ETA over ETB are described herein.
    Type: Application
    Filed: May 30, 2001
    Publication date: February 14, 2002
    Inventors: Bernard Joseph Banks, Nathan Anthony Logan Chubb, James John Eshelby, Michael Stephen Pacey, Darren John Schulz
  • Publication number: 20020012977
    Abstract: The following invention relates to a process for oxidizing alkyl groups attached directly or via a linker, to a sulfonamide moiety (II) by the use of cytochrome P450 enzymes, to give the corresponding alcohol or carboxylic acid (I).
    Type: Application
    Filed: May 29, 2001
    Publication date: January 31, 2002
    Inventor: Michael Stephen Pacey
  • Publication number: 20020004487
    Abstract: Erythromycins, particularly ones with novel C-13 substituents R1 (e.g. C3-C6 cycloalkyl or cycloalkenyl groups) are prepared by fermenting suitable organisms in the presence of R1CO2H. A preferred organism is Saccharopolyspora erythraea preferably containing an integrated plasmid capable of directing synthesis of desired compounds.
    Type: Application
    Filed: June 29, 2001
    Publication date: January 10, 2002
    Inventors: Peter Francis Leadlay, James Staunton, Jesus Cortes, Michael Stephen Pacey
  • Publication number: 20010016598
    Abstract: Erythromycins, particularly with C-13 substituents R1 (e.g. C3-C4 cycloalkyl or cycloalkenyl groups) are prepared by fermenting suitable organisms in the presence of R1CO2H. A preferred organism is Saccharopolyspora erythraea preferably containing an integrated plasmid capable of directing synthesis of desired compounds.
    Type: Application
    Filed: September 16, 1999
    Publication date: August 23, 2001
    Inventors: PETER FRANCIS LEADLAY, JAMES STAUNTON, JESUS CORTES, MICHAEL STEPHEN PACEY
  • Patent number: 6271255
    Abstract: Erythromycins, particularly with C-13 substituents R1 (e.g. C3-C6 cycloalkyl or cycloalkenyl groups) are prepared by fermenting suitable organisms in the presence of R1CO2H. A preferred organism is Saccharopolyspora erythraea preferably containing an integrated plasmid capable of directing synthesis of desired compounds.
    Type: Grant
    Filed: September 16, 1999
    Date of Patent: August 7, 2001
    Assignees: Biotica Technology Limited, Pfizer, Inc.
    Inventors: Peter Francis Leadlay, James Staunton, Jesus Cortes, Michael Stephen Pacey
  • Patent number: 5981500
    Abstract: A 5-oximino-25-substituted avermectin B1 or B2 monosaccharide of formula I herein has use in the treatment of parasitic infections in animals and humans. The compounds may be prepared from corresponding 5-keto substituted derivatives.
    Type: Grant
    Filed: May 9, 1997
    Date of Patent: November 9, 1999
    Assignee: Pfizer Inc.
    Inventors: Bernard Frank Bishop, Michael Stephen Pacey, David Austen Perry